Author

Bryan Sepulveda

Observed name: B. Sepulveda

Institution: Audentes Therapeutics (United States)

Observed institutions: Audentes Therapeutics (United States), Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5013397231

Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies

2013 · Paul Davies, Kelly M. Hinkle, et al. · Biochemical Journal · 88

Flotillin-Mediated Endocytic Events Dictate Cell Type-Specific Responses to Semaphorin 3A

2010 · Ioana Carcea, Avi Ma'ayan, et al. · Journal of Neuroscience · 54

Short- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth

2013 · Bryan Sepulveda, Roxana Mesias, et al. · PLoS ONE · 47

INCEPTUS Natural History, Run-in Study for Gene Replacement Clinical Trial in X-Linked Myotubular Myopathy

2022 · James J. Dowling, for the INCEPTUS investigators, et al. · Journal of Neuromuscular Diseases · 29

Effects of gene replacement therapy with resamirigene bilparvovec (AT132) on skeletal muscle pathology in X-linked myotubular myopathy: results from a substudy of the ASPIRO open-label clinical trial

2023 · Michael W. Lawlor, Benedikt Schoser, et al. · EBioMedicine · 13

eP245: INCEPTUS multinational, prospective, natural history, run-in study of males with X-linked myotubular myopathy

2022 · Perry Shieh, Wolfgang Müller-Felber, et al. · Genetics in Medicine

INCEPTUS Multinational, Prospective, Natural History, Run-in Study of Males with X-Linked Myotubular Myopathy

2021 · A. Blaschek, J. J. Dowling, et al. · Neuropediatrics

Works count: 7

Citation count: 231

H-index: 5

I10-index: 5